COMPASS THERAPEUTICS INC CMPX
COM · Common Stock · CUSIP 20454B104
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- HeadquartersBoston, MA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 101.3m as of 2022-07-25, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $2.65.
Trends to Q2 2022
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2021 | 38 |
| Q1 2022 | 35 |
| Q2 2022 | 35 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2022 | 13 | 15 |
| Q2 2022 | 12 | 13 |
Biggest buyers
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Added | +2.1m |
| Foresite Capital Opportunity Management V, LLC | Added | +454.2k |
| ORBIMED ADVISORS LLC | Added | +317.9k |
| BlackRock Inc. | New | +163.4k |
| JANUS HENDERSON GROUP PLC | Added | +153.9k |
| RENAISSANCE TECHNOLOGIES LLC | Added | +52.9k |
| New Capital Management LP | New | +24.2k |
| MARSHALL WACE, LLP | New | +23.7k |
| FLAGSHIP HARBOR ADVISORS, LLC | New | +14.0k |
| DAFNA Capital Management LLC | Added | +2.0k |
Biggest sellers
| Consonance Capital Management LP | Reduced | -1.9m |
| RA CAPITAL MANAGEMENT, L.P. | Sold out | -533.0k |
| CM Management, LLC | Reduced | -270.0k |
| Alphabet Inc. | Sold out | -192.8k |
| Ikarian Capital, LLC | Sold out | -74.2k |
| VANGUARD GROUP INC | Reduced | -70.9k |
| SALEM INVESTMENT COUNSELORS INC | Reduced | -70.0k |
| Qube Research & Technologies Ltd | Sold out | -52.8k |
| Monashee Investment Management LLC | Reduced | -39.8k |
| MORGAN STANLEY | Reduced | -26.4k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| TANG CAPITAL MANAGEMENT LLC 13G · passive investor no change · filed 2025-11-14 | 10.0% |
ORBIMED ADVISORS LLC
13D · may seek influence
-2.1 pts · filed 2025-08-15
Stated purposeThe Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either… Full filing |
8.9% |
| SUVRETTA CAPITAL MANAGEMENT, LLC 13G · passive investor +3.0 pts · filed 2025-08-21 | 8.2% |
| STATE STREET CORP 13G · institution new · filed 2026-08-07 | 5.5% |
| BlackRock, Inc. 13G · institution +0.6 pts · filed 2026-01-21 | 5.2% |
Fell to 5% or below in the last year: Vivo Opportunity Fund Holdings, L.P. (4.0%, 2026-08-14), BIOTECHNOLOGY VALUE FUND L P (4.3%, 2026-05-15), Blackstone Holdings II L.P. (3.4%, 2026-02-13)
Insider purchases and sales in Q2 2022
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2020 | 0 | — | 0 | — | — |
| Q4 2020 | 0 | — | 0 | — | — |
| Q1 2021 | 0 | — | 0 | — | — |
| Q2 2021 | 0 | — | 0 | — | — |
| Q3 2021 | 0 | — | 0 | — | — |
| Q4 2021 | 2 | $18.8m | 0 | — | — |
| Q1 2022 | 0 | — | 0 | — | — |
| Q2 2022 | 3 | $1.1m | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2022-06-21 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, director | Bought | $56.0k20.0k shares |
| 2022-06-16 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, director | Bought | $46.8k20.0k shares |
| 2022-06-13 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, director | Bought | $68.7k30.0k shares |
| 2022-06-06 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, director | Bought | $84.9k30.0k shares |
| 2022-06-01 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, director | Bought | $60.6k20.0k shares |
| 2022-05-26 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, director | Bought | $60.8k20.0k shares |
| 2022-05-23 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, director | Bought | $49.9k18.4k shares |
| 2022-05-17 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, director | Bought | $49.9k20.2k shares |
| 2022-05-13 | ORBIMED ADVISORS LLC +2 Director · See Footnotes | Bought | $76.5k30.7k shares |
| 2022-05-13 | GORDON CARL L Director · See Footnotes | Bought | $76.5k30.7k shares |
| 2022-05-12 | ORBIMED ADVISORS LLC +2 Director · See Footnotes | Bought | $228.2k97.1k shares |
| 2022-05-12 | GORDON CARL L Director · See Footnotes | Bought | $228.2k97.1k shares |
| 2022-05-11 | ORBIMED ADVISORS LLC +2 Director · See Footnotes | Bought | $115.8k64.7k shares |
| 2022-05-11 | GORDON CARL L Director · See Footnotes | Bought | $115.8k64.7k shares |
| 2022-05-10 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, director | Bought | $50.1k27.8k shares |
| 2022-05-10 | ORBIMED ADVISORS LLC +2 Director · See Footnotes | Bought | $39.1k24.4k shares |
| 2022-05-10 | GORDON CARL L Director · See Footnotes | Bought | $39.1k24.4k shares |
| 2022-05-09 | GORDON CARL L Director · See Footnotes | Bought | $141.5k90.7k shares |
| 2022-05-09 | ORBIMED ADVISORS LLC +2 Director · See Footnotes | Bought | $141.5k90.7k shares |
| 2022-05-06 | GORDON CARL L Director · See Footnotes | Bought | $16.6k10.2k shares |
| 2022-05-06 | ORBIMED ADVISORS LLC +2 Director · See Footnotes | Bought | $16.6k10.2k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q2 2022
| Manager | Shares | Change |
|---|---|---|
| ORBIMED ADVISORS LLC 1.06% of their portfolio | 22.0m $58.2m | Added +317.9k |
| FMR LLC 0.00% of their portfolio | 6.9m $18.2m | Unchanged |
| Rock Springs Capital Management LP 0.41% of their portfolio | 5.3m $14.1m | Unchanged |
| ADAGE CAPITAL PARTNERS GP, L.L.C. 0.03% of their portfolio | 4.4m $11.7m | Added +2.1m |
| Foresite Capital Management V, LLC 8.15% of their portfolio | 4.4m $11.7m | Unchanged |
| JANUS HENDERSON GROUP PLC 0.01% of their portfolio | 3.3m $8.8m | Added +153.9k |
| CHI Advisors LLC 2.87% of their portfolio | 2.8m $7.5m | Unchanged |
| Vivo Capital, LLC 0.53% of their portfolio | 2.0m $5.3m | Unchanged |
| Avidity Partners Management LP 0.12% of their portfolio | 2.0m $5.3m | Unchanged |
| Consonance Capital Management LP 17.79% of their portfolio | 1.6m $4.2m | Reduced -1.9m |
| Foresite Capital Opportunity Management V, LLC 10.38% of their portfolio | 1.6m $4.1m | Added +454.2k |
| Blackstone Inc. 0.01% of their portfolio | 1.5m $4.0m | Unchanged |
| VANGUARD GROUP INC 0.00% of their portfolio | 1.5m $4.0m | Reduced -70.9k |
| Monashee Investment Management LLC 1.19% of their portfolio | 1.2m $3.3m | Reduced -39.8k |
| FRED ALGER MANAGEMENT, LLC 0.01% of their portfolio | 608.5k $1.6m | Unchanged |
| DAFNA Capital Management LLC 0.14% of their portfolio | 198.1k $525.0k | Added +2.0k |
| BlackRock Inc. 0.00% of their portfolio | 163.4k $433.0k | New |
| LMR Partners LLP 0.00% of their portfolio | 100.0k $265.0k | Unchanged |
| RENAISSANCE TECHNOLOGIES LLC 0.00% of their portfolio | 66.2k $175.0k | Added +52.9k |
| SALEM INVESTMENT COUNSELORS INC 0.00% of their portfolio | 30.0k $80.0k | Reduced -70.0k |
| CM Management, LLC 0.09% of their portfolio | 30.0k $80.0k | Reduced -270.0k |
| MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio | 27.9k $74.0k | Reduced -10.7k |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 24.9k $65.0k | Unchanged |
| New Capital Management LP 0.04% of their portfolio | 24.2k $69.0k | New |
| MARSHALL WACE, LLP 0.00% of their portfolio | 23.7k $63.0k | New |
| Mascoma Wealth Management LLC 0.01% of their portfolio | 15.7k $42.0k | Unchanged |
| B. Riley Wealth Management, Inc. 0.00% of their portfolio | 14.9k $40.0k | Unchanged |
| FLAGSHIP HARBOR ADVISORS, LLC 0.00% of their portfolio | 14.0k $37.0k | New |
| UBS Group AG 0.00% of their portfolio | 7.2k $19.0k | Unchanged |
| Charter Oak Capital Management, LLC 0.00% of their portfolio | 1.5k $4.0k | Unchanged |
| CITIGROUP INC 0.00% of their portfolio | 1.4k $4.0k | New |
| MORGAN STANLEY 0.00% of their portfolio | 613 $2.0k | Reduced -26.4k |
| ROYAL BANK OF CANADA 0.00% of their portfolio | 228 $1.0k | Reduced -555 |
| OSAIC HOLDINGS, INC. 0.00% of their portfolio | 100 $0 | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |